160 related articles for article (PubMed ID: 9353591)
21. Identification of CDK- and cyclin-like proteins in the eye of Bulla gouldiana.
Krucher NA; Roberts MH
J Neurobiol; 1994 Oct; 25(10):1200-6. PubMed ID: 7815054
[TBL] [Abstract][Full Text] [Related]
22. Common and reversible regulation of wild-type p53 function and of ribosomal biogenesis by protein kinases in human cells.
David-Pfeuty T; Nouvian-Dooghe Y; Sirri V; Roussel P; Hernandez-Verdun D
Oncogene; 2001 Sep; 20(42):5951-63. PubMed ID: 11593402
[TBL] [Abstract][Full Text] [Related]
23. Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription.
Schang LM; Phillips J; Schaffer PA
J Virol; 1998 Jul; 72(7):5626-37. PubMed ID: 9621021
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of post-transcriptional RNA processing by CDK inhibitors and its implication in anti-viral therapy.
Holcakova J; Muller P; Tomasec P; Hrstka R; Nekulova M; Krystof V; Strnad M; Wilkinson GW; Vojtesek B
PLoS One; 2014; 9(2):e89228. PubMed ID: 24586613
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological activity of olomoucine II.
Krystof V; Lenobel R; Havlícek L; Kuzma M; Strnad M
Bioorg Med Chem Lett; 2002 Nov; 12(22):3283-6. PubMed ID: 12392733
[TBL] [Abstract][Full Text] [Related]
26. CDK-inhibitor olomoucine inhibits cell death after exposure of cell lines to cytosine-arabinoside.
Papazisis KT; Geromichalos GD; Kouretas D; Dimitriadis KA; Kortsaris AH
Cancer Lett; 1999 Apr; 138(1-2):221-6. PubMed ID: 10378797
[TBL] [Abstract][Full Text] [Related]
27. Apoptosis of central and peripheral neurons can be prevented with cyclin-dependent kinase/mitogen-activated protein kinase inhibitors.
Maas JW; Horstmann S; Borasio GD; Anneser JM; Shooter EM; Kahle PJ
J Neurochem; 1998 Apr; 70(4):1401-10. PubMed ID: 9523556
[TBL] [Abstract][Full Text] [Related]
28. Slowed N-type calcium channel (CaV2.2) deactivation by the cyclin-dependent kinase inhibitor roscovitine.
Buraei Z; Anghelescu M; Elmslie KS
Biophys J; 2005 Sep; 89(3):1681-91. PubMed ID: 15951378
[TBL] [Abstract][Full Text] [Related]
29. Functional genomics identify Birc5/survivin as a candidate gene involved in the chronotoxicity of cyclin-dependent kinase inhibitors.
Siffroi-Fernandez S; Dulong S; Li XM; Filipski E; Gréchez-Cassiau A; Peteri-Brünback B; Meijer L; Lévi F; Teboul M; Delaunay F
Cell Cycle; 2014; 13(6):984-91. PubMed ID: 24552823
[TBL] [Abstract][Full Text] [Related]
30. The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382.
Ljungman M; Paulsen MT
Mol Pharmacol; 2001 Oct; 60(4):785-9. PubMed ID: 11562441
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors.
Wang D; de la Fuente C; Deng L; Wang L; Zilberman I; Eadie C; Healey M; Stein D; Denny T; Harrison LE; Meijer L; Kashanchi F
J Virol; 2001 Aug; 75(16):7266-79. PubMed ID: 11461999
[TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.
Raynaud FI; Whittaker SR; Fischer PM; McClue S; Walton MI; Barrie SE; Garrett MD; Rogers P; Clarke SJ; Kelland LR; Valenti M; Brunton L; Eccles S; Lane DP; Workman P
Clin Cancer Res; 2005 Jul; 11(13):4875-87. PubMed ID: 16000586
[TBL] [Abstract][Full Text] [Related]
33. Transcription of herpes simplex virus immediate-early and early genes is inhibited by roscovitine, an inhibitor specific for cellular cyclin-dependent kinases.
Schang LM; Rosenberg A; Schaffer PA
J Virol; 1999 Mar; 73(3):2161-72. PubMed ID: 9971799
[TBL] [Abstract][Full Text] [Related]
34. A role for cyclin-dependent kinase(s) in the modulation of fast anterograde axonal transport: effects defined by olomoucine and the APC tumor suppressor protein.
Ratner N; Bloom GS; Brady ST
J Neurosci; 1998 Oct; 18(19):7717-26. PubMed ID: 9742142
[TBL] [Abstract][Full Text] [Related]
35. Cell differentiation, caspase inhibition, and macromolecular synthesis blockage, but not BCL-2 or BCL-XL proteins, protect SH-SY5Y cells from apoptosis triggered by two CDK inhibitory drugs.
Ribas J; Boix J
Exp Cell Res; 2004 Apr; 295(1):9-24. PubMed ID: 15051486
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.
De Azevedo WF; Leclerc S; Meijer L; Havlicek L; Strnad M; Kim SH
Eur J Biochem; 1997 Jan; 243(1-2):518-26. PubMed ID: 9030780
[TBL] [Abstract][Full Text] [Related]
37. Cyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick Type C mice.
Zhang M; Li J; Chakrabarty P; Bu B; Vincent I
Am J Pathol; 2004 Sep; 165(3):843-53. PubMed ID: 15331409
[TBL] [Abstract][Full Text] [Related]
38. The radiosensitising effect of olomoucine derived synthetic cyclin-dependent kinase inhibitors.
Korinkova G; Cwiertka K; Paprskarova M; Dzubak P; Hajduch M
Neoplasma; 2010; 57(2):161-9. PubMed ID: 20099981
[TBL] [Abstract][Full Text] [Related]
39. A new, unexpected action of olomoucine, a CDK inhibitor, on normal human cells: up-regulation of CLIMP-63, a cytoskeleton-linking membrane protein.
Wesierska-Gadek J; Gueorguieva M; Kramer MP; Ranftler C; Sarg B; Lindner H
J Cell Biochem; 2007 Dec; 102(6):1405-19. PubMed ID: 17975794
[TBL] [Abstract][Full Text] [Related]
40. Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases.
Abraham RT; Acquarone M; Andersen A; Asensi A; Bellé R; Berger F; Bergounioux C; Brunn G; Buquet-Fagot C; Fagot D
Biol Cell; 1995; 83(2-3):105-20. PubMed ID: 7549905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
